据港交所官网信息，2月25日，此前招股书失效的天辰生物医药（苏州）股份有限公司-B（以下简称"天辰生物"）再次提交 招股书，国金证券（香港）仍为其独家保荐人。 | 25/02/2026 | 天辰生物醫藥（蘇州）股份有限公司-B | | --- | --- | | | 25/02/2026 整體協調人公告 - 委任 歴 | | | 25/02/2026 申請版本（第一次呈交 ）全文檔案 [四] 多檔案 〉 | 展望未来，公司预计将持续录得亏损，且随着公司加大研发投入和加强销售及营销活动，预计亏损可能会增加。截至2023 年及2024年12月31日止年度以及截至2025年9月30日止九个月，公司经营活动所用的净现金流量分别为人民币60.9百万元、 人民币104.1百万元及人民币90.8百万元。 | | 截至12月31日止年度 | | 截至9月30日止九個月 | | | --- | --- | --- | --- | --- | | | 2023年 | 2024年 | 2024年 | 2025年 | | | 人民幣千元 | 人民幣千元 | 人民幣千元 | 人民幣千元 | | 經營活動所用現金流量淨額 | (60,8 ...

免责声明：本文内容与数据由观点根据公开信息整理，不构成投资建议，使用前请核实。 据招股书，天辰生物医药是一家致力于创新药开发的临床阶段生物制药公司，主要专注于针对过敏性及 自身免疫性疾病的生物药物的自主发现与开发。天辰生物医药已构建针对鼻科、皮肤科、呼吸科、血液 科、肾脏科及其他自身免疫性疾病的综合性生物制剂产品管线。 来源：观点地产网 观点网讯：2月25日，天辰生物医药（苏州）股份有限公司向港交所提交上市申请书，独家保荐人为国 金证券（香港）。 ...

天辰生物医药(苏州)股份有限公司(简称：天辰生物医药)于2025年8月21日所递交的港股招股书满6个月，于2026年2月21日失效，递表时国金证券(香港)为独 家保荐人。 | 21/08/2025 | 天辰生物醫藥（蘇州）股份有限公司 - B | | --- | --- | | | 01/09/2025 整體協調人公告 - 委任（經修訂） | | | 21/08/2025 申請版本（第一次呈交）全文檔案 [四] 多檔案 | | | 前提交文件: | | | 21/08/2025 整體協調人公告 - 委任 [四 | 基于全球及中国自身免疫性疾病和过敏性疾病市场的预期增长，天辰生物医药已经并将继续依托(i)在开发创新药方面的专业知识;(ii)两个自主研发的技术平 台(即高亲和力抗体发现平台和双功能抗体开发平台);及(iii)强大的研发能力，自主研发针对过敏性疾病及自身免疫性疾病的创新药。 据招股书，天辰生物医药是一家致力于创新药开发的临床阶段生物制药公司，主要专注于针对过敏性及自身免疫性疾病的生物药物的自主发现与开发。天辰 生物医药已构建针对鼻科、皮肤科、呼吸科、血液科、肾脏科及其他自身免疫性疾病的综合性生物制剂 ...

智通财经APP获悉，天辰生物医药(苏州)股份有限公司(简称：天辰生物医药)于2025年8月21日所递交的 港股招股书满6个月，于2026年2月21日失效，递表时国金证券(香港)为独家保荐人。 据招股书，天辰生物医药是一家致力于创新药开发的临床阶段生物制药公司，主要专注于针对过敏性及 自身免疫性疾病的生物药物的自主发现与开发。天辰生物医药已构建针对鼻科、皮肤科、呼吸科、血液 科、肾脏科及其他自身免疫性疾病的综合性生物制剂产品管线。 | 21/08/2025 | 天辰生物醫藥（蘇州）股份有限公司-B | 失效 | | --- | --- | --- | | | 01/09/2025 整體協調人公告 - 委任(經修訂) [四 | | | | 21/08/2025 申請版本(第一次星交)全文檔案 [0] 多檔案> | | | | CHANGE COLORIES | | | | 前提交文件: | | | | 21/08/2025 整體協調人公告 - 委任 □□ | | 基于全球及中国自身免疫性疾病和过敏性疾病市场的预期增长，天辰生物医药已经并将继续依托(i)在开 发创新药方面的专业知识;(ii)两个自主研发的技术平台( ...

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has requested Tianchen Biopharma to provide supplementary information regarding its overseas listing application, focusing on fundraising estimates and shareholder transparency [1][2] Group 1: Regulatory Requirements - CSRC requires Tianchen Biopharma to clarify the expected fundraising amount after the full exercise of the over-allotment option [1][2] - The company must disclose the situation regarding its shareholders, specifically OFC Bohui Fund and OFC Jiazi Fund, after upward penetration [1] - Legal opinions are required to confirm the company's compliance with foreign investment policies and necessary qualifications for its business operations [1] Group 2: Company Overview - Tianchen Biopharma is a clinical-stage biopharmaceutical company focused on the development of innovative drugs for allergic and autoimmune diseases [2] - The company has established a comprehensive pipeline of biopharmaceutical products targeting various medical fields, including otolaryngology, dermatology, respiratory, hematology, nephrology, and other autoimmune diseases [2] - The growth of the global and Chinese markets for autoimmune and allergic diseases supports Tianchen Biopharma's ongoing reliance on its expertise in innovative drug development and strong R&D capabilities [2]

Core Viewpoint - Tianchen Biopharmaceuticals (Suzhou) Co., Ltd. has submitted its listing application, focusing on the development of biopharmaceuticals for allergic and autoimmune diseases, with significant financial losses reported since its establishment in 2020 [1][2]. Financial Performance - Tianchen Biopharmaceuticals has not generated any revenue since its inception, reporting losses of RMB 95.778 million, RMB 137.321 million, and RMB 94.208 million for the years 2023, 2024, and the first half of 2025, respectively, totaling approximately RMB 327 million over two and a half years [1][2]. - The company anticipates continued losses due to increased R&D investments and enhanced sales and marketing activities [2]. Cash Flow and Financing - The net cash flow from operating activities has shown a negative trend, with outflows of RMB 60.865 million, RMB 104.122 million, and RMB 47.673 million for the years 2023, 2024, and the first half of 2025, respectively [3][4]. - As of June 30, 2025, the company had cash and cash equivalents amounting to RMB 136.118 million, with financial assets valued at RMB 155 million [3]. Supply Chain Concentration - The company has a moderately concentrated supply chain, with purchases from the top five suppliers accounting for 48.58%, 51.65%, and 57.93% of total procurement for the years 2023, 2024, and the first half of 2025, respectively [4][5]. - Although this concentration is not deemed significantly high, the company is actively implementing strategies to mitigate potential risks, including diversifying supply bases and closely monitoring supplier performance [5].